Analysis of Clinical Parameters, Drug Consumption and Use of Health Resources in a Southern European Population with Diabetes That Did Not Contract COVID-19: A Longitudinal Big Data Study

Ana Lear-Claveras, Bárrbara Oliván-Blázquez, Ana Claverí, Sabela Couso-Viana and Rosa Magallón Botaya

Abstract: The lockdown measures imposed to stop the spread of the virus have affected the general population, but particularly people with chronic diseases such as diabetes. An observational real world data pre-post study of 86,615 individuals over the age of 16, having a medical history in the Aragon (Spain) Health Service and diagnosed with diabetes, without COVID-19 infection was undertaken. Clinical, pharmacological and health resource use variables were collected during the six months prior to the onset of the lockdown and during the six months after the lockdown ended. The Student’s t-test was used to analyse differences in means. Our study does not show clinically relevant changes six months following the end of the strict lockdown. The consumption, by these patients, of hypoglycaemic drugs and the use of health resources continue at below pre-pandemic levels, six months later. The interruption in care for these patients and the lifestyle change resulting from the pandemic do not appear to have had a significant impact on the health of the diabetic population.

Keywords: COVID-19; diabetes; lockdown; lifestyle; health resources

1. Introduction

The current COVID-19 pandemic has tested the response and ability of people, governments and health systems around the world to adapt [1]. Its impact on essential health services is of great concern. According to the results of the PULSE survey carried out by the World Health Organisation (WHO) in 105 countries, the majority (90%) have suffered interruptions in essential healthcare services since the beginning of the pandemic [2]. These interruptions are likely to have serious adverse effects on the health of the most vulnerable populations, such as those with chronic diseases who need regular assistance and care, especially Primary Care (PC) [2,3].

These PC services, which helped people to manage chronic diseases before COVID-19, were modified with the arrival of the pandemic. Since then, they have been focused on detecting mild cases of the infection, following up positive cases and contact tracing. This interrupted their care of patients with chronic diseases to a greater or lesser extent. In addition, to reduce the risk of COVID-19 transmission, medical appointments were postponed and follow-up appointments were mostly carried out by telephone [4].
The restrictions imposed under the state of emergency to stop the spread of the virus has also had a direct impact on people with chronic diseases, and especially on those with diabetes. The global prevalence of diabetes was 9.3% in 2019 [5]. In Spain, the figure was 13.8%, counting type 2 diabetics alone [6]. The home lockdown measures applied have affected the diabetic population’s ability to lead a healthy lifestyle (balanced diet, physical activity, etc.), which plays a very important role in the proper management and control of this disease [7].

Previous studies about the impact that lifestyle modifications have had on patients with diabetes have had varying results. Some suggest that lockdown has not had a negative impact on the disease’s clinical parameters [8,9], while others report the deterioration of patients during the time when restrictions were imposed [10,11].

The deterioration of the clinical parameters of diabetes, and other non-communicable diseases such as cardiovascular diseases or cancer during the pandemic, could further increase the risk of poor prognosis and mortality from COVID-19 [12]. An association between the presence of diabetes and a more serious COVID-19 disease has been found by many studies [13,14].

Most studies on diabetes and COVID-19 have investigated the influence of this disease on the prognosis of infected patients, but fewer have analysed the impact of the pandemic on the uninfected diabetic population. These latest studies also mostly have cross-sectional designs and small sample sizes, and it is, therefore, necessary to carry out large-scale studies that provide a longitudinal perspective.

Accordingly, this paper aims to study and conduct a longitudinal analysis of the possible changes in the clinical parameters, as well as in the hypoglycaemic drug consumption and the use of health resources, between the six months prior to the start of lockdown and the six months after the end of strict lockdown, in a southern European population with diabetes who did not contract COVID-19.

2. Materials and Methods

2.1. Design and Study Population

Observational real world data pre-post study of the population aged over 16 registered in the Autonomous Region of Aragon, in the north of Spain, with medical records in Primary Healthcare Centres (n = 1,122,151 people).

This study’s final sample is made up of individuals aged over 16 with a clinical history in the Aragon Health Service and a diagnosis of type 1 or type 2 diabetes, according to the International Classification of Primary Care (ICPC-2) criteria [15], who have not been infected with COVID-19 (n = 86,615). This last criterion was established to analyse changes in health status due exclusively to the measures imposed to control the pandemic. On 15 March 2020, the Spanish Government declared a state of national emergency, limiting mobility and requiring the population to stay at home until 3 May.

Data were collected from each individual at different time periods. The baseline measurement was taken in the six months prior to the start of lockdown (from 14 September 2019 to 15 March 2020), and the second measurement in the six months after the end of strict lockdown (until 4 November 2020).

2.2. Data Sources

This study is based on data from Aragon Primary Care centre’s longitudinal electronic health records.

Given that the healthcare system is universal, with practically no other Primary Care providers, it is considered that the data obtained in this study are representative of practically 100% of the population that met the study’s inclusion criteria.

2.3. Variables

The sociodemographic variables included in this study were: sex, age, pharmaceutical delivery and rurality of the health zones (defined as: rural—with less than
10,000 inhabitants—or urban—with more than 10,000 inhabitants). The number of deaths in the study population was also considered for each of the measurement periods.

Comorbidity with other chronic diseases was also considered. Those chronic conditions with a prevalence greater than 5% [16] were also collected (arrhythmias, heart failure, ischaemic heart disease, hypertension, dyslipidaemia, obesity, overweight, vein and artery disease, cerebrovascular disease, chronic bronchitis, chronic obstructive pulmonary disease (COPD), asthma, chronic kidney disease, hypo and hyperthyroidism, smoking, alcoholism, insomnia, anxiety and depression, autolytic attempt, anaemia, neoplasia, dementia, hearing loss, cataracts, glaucoma, osteoarthritis, osteoporosis and dorsopathy).

The variables of interest in our study are related to the clinical parameters of diabetes and its possible complications. The clinical parameters collected were: blood glucose level, glycated haemoglobin (HbA1c), blood creatinine and glomerular filtration. In addition, blood pressure measurements (systolic and diastolic), total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, weight and body mass index (BMI) were collected.

Patient drug use in the 6 months prior to the start of lockdown and in the 6 months after the end of strict lockdown was assessed through variations in the number of patients with diabetes who do not use hypoglycaemic drugs vis-à-vis those who consume one or more, and through the total number of defined daily doses (DDD) per 1000 inhabitants per day (DHD), dispensed by the pharmacy during each of the two periods. For the calculation of DHD, the Aragon population at the middle of each of the periods was used.

$$\text{DHD} = \frac{\text{Registered consumption of the active ingredient} \times 1000 \text{ inhabitants}}{\text{Standard DDD} \times \text{ninhabitants/period} \times 365 \text{ days}}$$

It was decided to take the dispensed DHD and not the prescribed one, as some prescribed drugs may not be dispensed. According to the Anatomical Therapeutic Chemical classification system (ATC), the following pharmacological groups were assessed: A10A (insulins and analogues) and A10B (oral antidiabetics).

Finally, these patients’ use of health system resources during the period under study was assessed using variables related to the use of PC services (number of nurse and general practitioner—GP—visits for ordinary or continuous care at a health centre or at home, and number of visits to other health centre professionals), and the use of specialised hospital services (number of visits to hospital’s specialised care, number of diagnostic tests performed, number of visits to accident and emergency—A&E—department, hospitalisations and admissions to intensive care unit—ICU—as well as the duration of these stays).

2.4. Statistical Analysis

Given our large sample size, we used parametric statistics [17]. To determine the characteristics of the population, and the total number of patients who take one or more hypoglycaemic drug, or none at all, a descriptive analysis of the study variables was carried out using frequencies (percentages) to summarise the categorical variables and measures of central tendency and dispersion (mean and standard deviation) for the continuous variables.

For the study population, mortality due to causes other than COVID-19 was assessed by calculating the crude mortality rate for each of the two periods. The Aragon population at the middle of each of the two periods was used as the denominator.

In order to ascertain the variations in clinical variables, if in any of the different periods of time (6 months prior to the start of lockdown or 6 months later) there was more than one measurement collected for the same clinical parameter, the median and the interquartile range (IQR) were calculated. For the two time periods, the mean and standard deviation (SD) of each of the clinical variables were calculated. To compare the difference of means between the two measurements a paired samples t-test was performed.

Differences in drug consumption were assessed through the DHDs dispensed in the pharmacy to the study population in each of the periods.
The mean and standard deviation of each variable of resource use (primary and hospital specialised care) were also calculated. A paired samples t-test was used to compare the difference of means too. For those variables with a fewer number of observations than 100, a Wilcoxon rank test was used.

The level of significance was established at 5% \((p < 0.05)\). The statistical analysis was carried out using IBM SPSS Statistic 21 (IBM Corporation, New York, NY, USA) and R version 4.0.5 (IBM Corporation, New York, NY, USA) in a PC with 16 MB of RAM.

3. Results

On 14 September 2019, there were 86,615 people over 16 years of age, with a diagnosis of diabetes (type 1 or type 2) in their PC history, who, as of 3 November 2020, had not been infected with COVID-19. It should be noted that for the population aged over 16, the prevalence of diabetes was 7.72% at the beginning of 2019. The mean age of the sample was 69.5 years (SD: 13.7), with 48,436 men (55.9%) and 38,179 women (44.1%). Two-thirds (69.5%) had annual incomes below 18,000 euros, and more than half (51.2%) resided in urban areas (with more than 10,000 inhabitants) (Table 1). Hypertension (66.1%), followed by dyslipidaemia (58.2%) and dorsopathies (28.9%) were the most prevalent comorbid diseases among the population with diabetes under study.

| Table 1. Sociodemographic data and chronic comorbidities in diabetic patients not infected with COVID-19. |
|---------------------------------------------------------------|
| **Age** | **Mean (SD)** | **N (%)** |
| Sex | | |
| Men | 69.5 (13.7) | 48,436 (55.9) |
| Women | | 38,179 (44.1) |
| Pharmaceutical delivery | | |
| <18,000 | | 60,182 (69.5) |
| Between 18,000 and 100,000 | | 22,140 (25.6) |
| >100,000 | | 336 (0.4) |
| Free pharmacy | | 3189 (3.7) |
| Mutualist | | 706 (0.8) |
| Uninsured | | 62 (0.1) |
| Rurality of health zones | | |
| Urban | | 44,321 (51.2) |
| Rural | | 42,293 (48.8) |
| Chronic comorbidities (Yes %) | | |
| Arrhythmias | | 9266 (10.7) |
| Heart failure | | 5023 (5.8) |
| Ischaemic heart disease | | 9633 (11.1) |
| Hypertension | | 57,295 (66.1) |
| Dyslipidaemia | | 50,431 (58.2) |
| Obesity | | 20,200 (23.3) |
| Overweight | | 1374 (1.6) |
| Vein/artery disease | | 4705 (5.4) |
| Cerebrovascular disease | | 7784 (9) |
| Chronic bronchitis | | 1354 (1.6) |
| COPD | | 5853 (6.8) |
| Asthma | | 4901 (5.7) |
| Chronic kidney disease | | 11,309 (13.1) |
| Hypothyroidism | | 9983 (11.5) |
| Hyperthyroidism | | 3932 (4.5) |
| Smoking | | 12,192 (14.1) |
| Alcoholism | | 1661 (1.9) |
| Insomnia | | 12,828 (14.8) |
| Anxiety and depression | | 23,289 (26.9) |
| Autolytic attempt | | 200 (0.2) |
Table 1. Cont.

| Condition      | N (%)            |
|----------------|------------------|
| Anaemia        | 16,927 (19.5)    |
| Neoplasia      | 23,682 (27.3)    |
| Dementia       | 3725 (4.3)       |
| Hearing loss   | 8914 (10.3)      |
| Cataracts      | 15,300 (17.7)    |
| Glaucoma       | 9838 (11.4)      |
| Osteoarthritis | 10,124 (11.7)    |
| Osteoporosis   | 7772 (9.0)       |
| Dorsopathy     | 25,051 (28.9)    |

(SD) Standard deviation; (COPD) Chronic Obstructive Pulmonary Disease.

Of the individuals included in the study, 1887 died over the six months prior to the declaration of the state of emergency, and 2019 during the six months following the end of the lockdown. Taking into account the Aragon population during these two periods, the mortality rate per 1000 individuals was 1.4 [95%CI 1.4–1.5] and 1.5 [95%CI 1.5–1.6], respectively.

The variation in the clinical variables when comparing the two measurements, can be seen in Table 2. HbA1c parameters \(p < 0.001, 95\%\text{CI}: 0.04–0.11\], total cholesterol \(p < 0.001, 95\%\text{CI}: 2.39–5.00\], LDL cholesterol \(p < 0.001, 95\%\text{CI}: 2.61–4.84\], weight \(p < 0.001, 95\%\text{CI}: 0.54–0.65\] and BMI \(p < 0.001, 95\%\text{CI}: 0.17–0.24\] show a significant trend towards a slight improvement. This is in contrast to the improvement observed in blood glucose and HDL cholesterol, which is only statistically significant for this last parameter \(p = 0.032, 95\%\text{CI}: 0.04–0.94\). In the same table, we can observe a subtle deterioration for other variables such as blood creatinine \(p < 0.001, 95\%\text{CI}: −0.04–−0.02\] and a decrease in the glomerular filtration rate \(p < 0.001, 95\%\text{CI}: 1.28–1.95\]; both are statistically significant variations. For blood pressure six months after lockdown ended, only diastolic blood pressure experienced a statistically significant deterioration \(p < 0.001, 95\%\text{CI}: −0.42–−0.22\).

Table 2. Clinical parameters 6 months before and 6 months after lockdown.

|                      | 6 Months Before | 6 Months After | Paired Samples t-Test |
|----------------------|-----------------|----------------|-----------------------|
|                      | N        | Mean (SD)      | 95%CI                 | p         |
| Blood glucose level  | 2910    | 137.2 (38.6)   | 135.8 (41.2)          | −0.06; 2.87 | 0.06     |
| HbA1c (%)            | 2518    | 7.0 (1.1)      | 6.9 (1.1)             | 0.04; 0.11 | <0.001   |
| Blood creatinine     | 2688    | 0.9 (0.4)      | 1.0 (0.4)             | −0.04; −0.02 | <0.001 |
| Glomerular filtration| 2688    | 75.5 (22.0)    | 73.8 (22.5)           | 1.28; 1.95 | <0.001   |
| Systolic blood pressure| 26,685 | 136.1 (14.3)  | 136.2 (15.4)          | −0.33; 0.01 | 0.073    |
| Diastolic blood pressure| 26,691 | 75.6 (8.8)     | 75.9 (9.3)            | −0.42; −0.22 | <0.001 |
| Total cholesterol    | 2708    | 179.6 (39.3)   | 175.9 (38.9)          | 2.39; 5.00 | <0.001   |
| LDL                  | 2459    | 100.2 (33.3)   | 96.5 (31.6)           | 2.61; 4.84 | <0.001   |
| HDL                  | 2638    | 50.8 (16.0)    | 50.3 (13.2)           | 0.04; 0.94 | 0.032    |
| Triglycerides        | 2669    | 145.9 (84.0)   | 147.5 (84.5)          | −4.08; 0.94 | 0.211    |
| Weight               | 17,095  | 78.3 (15.0)    | 77.7 (15.2)           | 0.54; 0.65 | <0.001   |
| BMI                  | 10,800  | 29.9 (5.0)     | 29.7 (5.1)            | 0.17; 0.24 | <0.001   |

(HbA1c) Glycated haemoglobin; (LDL) Low density lipoprotein; (HDL) High density lipoprotein; (BMI) Body mass index; (SD) Standard deviation; (95%CI) Confidence interval.

In terms of drug use by patients with diabetes in the six months before the start of the lockdown and six months after lockdown, Table 3 shows an increase in the total number of patients who did not take any hypoglycaemic drugs [38,032 (43.9) vs. 40,568 (46.8)], and a decrease in the total number of patients who took one or more drugs. Table 4 also reveals a decrease in the total number of DHDs dispensed by pharmacies for all drugs...
included in the study, except for the insulins Aspart, Glargine and Degludec and the oral antidiabetic Metformin.

Table 3. Number of patients who do not use insulins or oral antidiabetics or who consume one or more.

|                                | 6 Months Before | 6 Months After |
|--------------------------------|-----------------|----------------|
| No hypoglycaemic drug          | 38,032 (43.9)   | 40,568 (46.8)  |
| One hypoglycaemic drug         | 36,360 (42.0)   | 34,461 (39.8)  |
| Two hypoglycaemic drugs        | 10,325 (12.0)   | 9,968 (11.5)   |
| Three or more hypoglycaemic drugs | 1898 (2.1)     | 1618 (1.9)     |

Table 4. Number of DHDs 6 months before and 6 months after lockdown.

|                                | 6 Months Before | 6 Months After |
|--------------------------------|-----------------|----------------|
| Insulins                       |                 |                |
| Insulin (human) fast acting    | 655             | 0.63           |
| Lispro fast acting             | 2106            | 4.15           |
| Aspart fast acting             | 5490            | 9.13           |
| Glulisine                      | 1179            | 2.05           |
| Insulin (human) intermediate acting | 448           | 1.01           |
| Insulin (human) intermediate acting + fast acting | 255          | 0.70           |
| Lispro intermediate acting     | 922             | 2.71           |
| Aspart intermediate acting     | 1591            | 5.10           |
| Glargine                       | 14,491          | 22.70          |
| Determir                       | 1620            | 3.26           |
| Degludec                       | 3060            | 4.44           |

Oral antidiabetics

|                                |                 |                |
| Metformin                      | 31,076          | 39.96          |
| Glibenclamide                  | 289             | 0.46           |
| Glipizide                      | 110             | 0.21           |
| Gliclazide                     | 2369            | 4.25           |
| Glimepiride                    | 1951            | 7.26           |
| Glisentide                     | 5               | 0.01           |

(DHDs) Defined Daily Doses per 1000 inhabitants per day.

The use that the population with diabetes made of health resources can be seen in Table 5. Between the two measurement periods, the number of nurse and general practitioner visits decreased; with only the decrease in the number of nurse visits (continuous care), including those at the health centre and home visits, not being statistically significant. On the other hand, the same table shows an increase in the number of general practitioner visits (continuous care) at the health centre [$p = 0.014$, 95%CI: $−0.14−−0.02$], and the number of visits to other professionals, such as social workers [$p = 0.020$, 95%CI: $−0.71−−0.06$]. As for physiotherapy services, visits were considerably reduced compared to the baseline measurement [$p = 0.006$, 95%CI: $0.34–2.04$].
Table 5. Number of visits and diagnostic tests prescribed 6 months before and 6 months after lockdown.

|                                      | 6 Months Before | 6 Months After | Paired Samples t-Test |
|--------------------------------------|-----------------|----------------|-----------------------|
|                                      | N               | Mean (SD)      | 95%CI                 | p          |
| No. of nursing visits (ordinary care) at health centre or by telephone | 54,995          | 5.26 (5.27)    | 4.53 (4.85)           | 0.68; 0.76 | <0.001 |
| No. of nursing visits (ordinary care) at home                              | 4985            | 7.03 (9.94)    | 6.70 (9.80)           | 0.04; 0.60 | 0.023  |
| No. of nursing visits (continuous care) at health centre                     | 2108            | 2.31 (3.53)    | 2.19 (3.57)           | −0.03; 0.27| 0.112  |
| No. of nursing visits (continuous care) at home                              | 621             | 2.30 (2.99)    | 2.28 (3.67)           | −0.30; 0.35| 0.861  |
| No. of general practitioner visits (ordinary care) at health centre or by telephone | 68,803          | 5.36 (4.24)    | 5.29 (4.72)           | 0.03; 0.10 | <0.001 |
| No. of general practitioner visits (ordinary care) at home                  | 2811            | 3.44 (3.67)    | 2.80 (3.33)           | 0.51; 0.77 | <0.001 |
| No. of general practitioner visits (continuous care) at health centre        | 4458            | 1.85 (1.82)    | 1.93 (2.19)           | −0.14; −0.02| 0.014  |
| No. of general practitioner visits (continuous care) at home                 | 682             | 1.84 (1.63)    | 1.68 (1.38)           | 0.03; 0.28 | 0.014  |
| No. of visits to other professionals                                         |                 |                |                       |            |
| Physiotherapist                                                               | 294             | 5.63 (6.13)    | 4.43 (6.16)           | 0.34; 2.04 | 0.006  |
| Midwife                                                                       | 141             | 2.45 (2.16)    | 2.52 (2.06)           | −0.53; 0.37| 0.732  |
| Dentist                                                                       | 257             | 2.15 (1.82)    | 2.41 (1.88)           | −0.55; 0.04| 0.092  |
| Social worker                                                                 | 426             | 2.75 (2.65)    | 3.13 (3.45)           | −0.71; −0.06| 0.020  |
| No. of visits to specialised care (first consultation)                        | 3105            | 1.49 (0.87)    | 1.53 (0.93)           | −0.08; 0.00| 0.067  |
| No. of visits to specialised care (successive consultations)                  | 26,307          | 2.71 (2.27)    | 2.61 (2.38)           | 0.07; 0.12 | <0.001 |
| No. of diagnostic tests performed                                             |                 |                |                       |            |
| X-rays                                                                         | 12,895          | 1.18 (1.34)    | 1.03 (1.26)           | 0.12; 0.18 | <0.001 |
| Ultrasound                                                                     | 12,895          | 0.33 (0.58)    | 0.30 (0.54)           | 0.01; 0.04 | <0.001 |
| Resonance                                                                      | 12,895          | 0.11 (0.36)    | 0.12 (0.35)           | −0.01; 0.00| 0.148  |
| CT scans                                                                       | 12,895          | 0.36 (0.67)    | 0.37 (0.68)           | −0.03; −0.00| 0.028  |
| Retinographies                                                                 | 41              | 1.02 (0.16)    | 1.15 (0.65)           | −0.33; 0.09| 0.257 a|
| Other imaging test                                                             | 12,895          | 0.15 (0.43)    | 0.14 (0.41)           | 0.00; 0.02 | 0.019  |
| Haemograms                                                                     | 22,398          | 0.31 (0.54)    | 0.22 (0.48)           | 0.08; 0.09 | <0.001 |
| Biochemistry                                                                   | 22,398          | 1.05 (0.65)    | 0.98 (0.64)           | 0.05; 0.07 | <0.001 |
| Microbiology                                                                   | 22,398          | 0.18 (0.56)    | 0.24 (0.64)           | −0.07; −0.05| <0.001 |
| Immunology test                                                                | 22,398          | 0.14 (0.40)    | 0.13 (0.38)           | 0.01; 0.02 | <0.001 |
| Coagulation                                                                    | 22,398          | 0.03 (0.17)    | 0.04 (0.20)           | −0.01; −0.00| <0.001 |
| Urine test                                                                     | 22,398          | 0.40 (0.61)    | 0.36 (0.60)           | 0.03; 0.05 | <0.001 |
| No. of visits to the emergency department                                      | 4333            | 1.78 (1.50)    | 1.66 (1.29)           | 0.06; 0.16 | <0.001 |
| No. of hospital admissions                                                     | 1335            | 1.54 (1.04)    | 1.54 (1.05)           | −0.07; 0.06| 0.926  |
| No. of days of hospital stay                                                   | 1335            | 18.70 (56.44)  | 17.37 (45.54)         | −0.30; 2.95| 0.111  |
| No. of ICU admissions                                                          | 5               | 1 (0)          | 1 (0)                 | (0) (*)     |
| No. of days of ICU stay                                                        | 5               | 22.20 (27.36)  | 18.60 (27.59)         | −5.20; 12.40| 0.465 (*) |

(*) The correlation and t cannot be calculated because the standard error of the differences is 0. a Wilcoxon signed-rank test. (ICU) Intensive care unit; (SD) Standard deviation; (95%CI) Confidence interval.
In relation to hospital specialised care, we observe the opposite trend. While the number of first visits to specialised care increased in the six months after the end of strict lockdown, the number of follow-up consultations decreased; this was the only statistically significant decrease \( p < 0.001, 95\%\text{CI}: 0.07–0.12 \).

The performance of diagnostic tests also changed during the months under study. These variations were statistically significant for all tests \( p < 0.05 \), except for resonances and retinographies.

Among these patients, the number of visits to A&E also decreased \( p < 0.001, 95\%\text{CI}: 0.06–0.16 \). In terms of hospitalisations and ICU admissions, no statistically significant differences were observed in terms of the number of visits or the duration of these stays.

4. Discussion

Unlike the results published by other studies \([10,11]\), our longitudinal, large-scale study does not show clinically relevant changes in the clinical parameters of diabetes, despite the observed interruptions in these patients’ care. These findings are consistent with the results of some previous studies that also report a neutral \([18,19]\), or even a positive \([7]\) influence of restrictive measures on glycaemic control in these patients.

When patients with type 1 and 2 diabetes are analysed separately, the results are more heterogeneous. A systematic review that analysed 33 studies which included patients with type 1 \( (n = 33) \) and 2 \( (n = 8) \) diabetes showed significant improvements in glycaemic values, mainly in patients with type 1 diabetes \([20]\). In our study, we were unable to differentiate between patients with type 1 or type 2 diabetes, but we assumed that the vast majority of patients were type 2 diabetics because: (a) in Spain type 1 diabetes accounts for 1 in 10 cases of diabetes \([21]\) and (b) the mean age of the sample was high.

One of the factors that could explain the slight impact of lockdown in the clinical parameters shown in our study is the knowledge the patients with diabetes themselves have of the influence that their disease has on their prognosis if infected with COVID-19 \([22]\). This could have promoted better disease management among patients with diabetes (more frequent glycaemic control, awareness of taking medication, etc.) \([23]\), and greater self-care \([19]\). This last would be reflected in the significant improvement in the total cholesterol, LDL, HDL, weight and BMI showed in our study. Some previous studies in this area have pointed to the possible improvement of dietary habits \([24]\) and physical exercise \([23,24]\) due to the lockdown in patients with diabetes.

This subtle improvement in clinical parameters could in turn explain the decrease in the consumption of hypoglycaemic drugs in the six months after the end of lockdown. Previous studies showed the same trend in terms of diabetes drug prescriptions \([25,26]\).

The decrease in the consumption of these drugs could also be explained by the difficulty of accessing them. According to the results of the study carried out in our country by a Patient Organisation Platform (POP) \([27]\), during the first wave of the pandemic, 79.3% of patients with chronic diseases found it difficult to access treatment. In the second wave, this percentage fell to 25.2%.

During the first months of the pandemic, to avoid the spread of the new virus, people with diabetes in Aragon (as in other places \([2,28]\)) had interruptions in primary health care. Nevertheless, they continued to have telephone consultations. This allowed these patients’ condition to be controlled and monitored \([29]\), which could have prevented any short-term deterioration. Very similar results were reported by two studies \([30,31]\) carried out in patients with type 2 diabetes.

However, not all care for these patients can be done properly remotely. Patients with diabetes (especially elderly patients with type 2 diabetes) have a high prevalence of metabolic risk factors and comorbid conditions and, therefore, require regularly, face-to-face attention \([32,33]\). For these most fragile patients, telematic attention could have been more difficult during the months of the pandemic \([30]\). As shown in another work \([34]\), the decrease in the number of nursing visits observed in our study could have represented a challenge in the nursing management of diabetic foot care during the COVID-19 pandemic.
According to the results of a study [35] carried out in Catalonia (Spain), diabetic foot screening was the most affected indicator among the quality standards that decreased the most during the pandemic.

Likewise, six months after the end of the strict home lockdown, the number of visits to specialised care and diagnostic tests conducted on patients with diabetes had not yet reached pre-pandemic levels. These results, are consistent with the results of other published works [2,28]. Diabetic retinopathy screening also showed a significant decrease in the study carried out in Catalonia [35]. In our study, the number of retinographies performed showed an opposite trend, however, these results were not statistically significant. According to the decrease in the number of visits to specialised care (successive consultations), another study conducted in England, showed a decrease in lower-limb major and minor amputation and revascularisation procedures among patients with diabetes in 2020 [36].

A mix between supply and demand was responsible for the disruption of services [2]. These interruptions could have caused a delay in the diagnosis and in the start of treatment, causing a worsening in clinical outcomes (decompensations or acute or chronic complications) in those more fragile individuals [2,28,33]. This fact could explain the increase in the number of deaths during the second measurement period, although this study does not include patients with diabetes who also contracted COVID-19, the excess of mortality due to other causes could have been caused by the concentration of resources in the fight against COVID-19. Another study also carried out in Spain reported similar results, showing a reduction in this trend in the first half of 2021 [37].

Our study has some limitations. Firstly, the dataset includes patients with both type 1 and type 2 diabetes, which means that it is dealing with patients with different clinical profiles. Secondly, for certain clinical variables, a limited number of records are available, because the GP must validate those results. Therefore, they are a sample of the real data. We cannot rule out the existence of a bias, although it is reasonable to consider that it would have the same size and direction in each of the periods considered. Thirdly, we do not know how long these patients have been diabetic. We also do not have information about the acute (hypoglycaemia, hyperglycaemia, diabetic ketoacidosis) and chronic (microvascular and macrovascular) complications of diabetes or the decompensation of other chronic diseases. Finally, this study also does not include self-reported data on disease management (glycaemic control, medication intake) and the lifestyle habits (diet, physical activity, work routine, etc.) maintained by the population under study during the months of lockdown. Conducting studies with a qualitative approach would provide information about the subjective perception that individuals have of the impact of lockdown on maintaining healthy lifestyles and managing their disease. Likewise, it would be interesting to evaluate the changes 12 months after the end of strict lockdown, to verify whether or not the clinical parameters follow the same trend over time.

Episodes, use of health resources and drug consumption, are routinely collected from a variety of sources for the total population. Greater knowledge about the health demand and the real consequences of pandemics and their secondary effects, may improve health planning and resource management. A more detailed analysis of geographic variations will allow the identification of vulnerable populations.

5. Conclusions

Our study contributes to the knowledge of the consequences of lockdown for the population of diabetes patients not infected with COVID-19 in a medium-size Spanish Health Authority. It offers a longitudinal perspective, considering variables related to clinical parameters, drug consumption and the use of health resources together.

Our results suggest that diabetes patients without COVID-19 have been able to cope adequately with the restrictions imposed, with no clinically significant impact on their diabetes control.
Author Contributions: Conceptualisation, B.O.-B. and R.M.B.; formal analysis, S.C.-V., A.C., B.O.-B. and A.L.-C.; writing—original draft preparation, A.L.-C.; writing—review and editing, B.O.-B., A.C. and R.M.B.; supervision, B.O.-B. and R.M.B. All authors have read and agreed to the published version of the manuscript.

Funding: This study has been funded by the Department for Science, Universities and the Knowledge Society of the Government of Aragon (Spain), through the DGACOVID-01 project. The funding source has not had a direct role in protocol design, data collection, analysis or data interpretation.

Institutional Review Board Statement: The procedures that constitute this work comply with the ethical standards of the Aragón Clinical Research Ethics Committee (belonging to the Department of Health of the Government of Aragon, Spain), and with the Declaration of Helsinki of 1975, and its version revised in 2008. The Study Protocol was approved by the Aragón Clinical Research Ethics Committee (PI20–175).

Informed Consent Statement: The data of the participating patients were obtained anonymously from the medical records provided by the Aragón Health Service. This report does not contain patient identifiable data. Consent from individuals involved in this study was not required. The treatment, communication and transfer of this personal data was in accordance with the provisions of Regulation (EU) 2016/679 of the European Parliament and Organic Law on the Protection of Personal Data and guarantee of digital rights 03/2018.

Data Availability Statement: This report does not contain patient identifiable data. Consent from individuals involved in this study was not required. Requests for any underlying data cannot be granted by the authors because the data was acquired under a license/data sharing agreement with the Aragon Health Services, under which conditions of use (and further use) apply.

Acknowledgments: We should like to thank: the Preventive Activity and Health Promotion Research Network (Red de Prevención y Promoción de la Salud en Atención Primaria/RedIAPP, Carlos III Institute of Health, Spain); the B21_20R Research Group of the Department of Research, Innovation and Universities of the Aragon Regional Authority (Spain); and the European Regional Development Fund (FEDER) “Otra forma de hacer Europa”.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Barone, M.T.U.; Villarroel, D.; de Luca, P.V.; Harnik, S.B.; Lima, B.L.S.; Weiselberg, R.J.P.; Giampaoli, V. COVID-19 impact on people with diabetes in South and Central America (SACA region). Diabetes Res. Clin. Pract. 2020, 166, 108301. [CrossRef] [PubMed]
2. World Health Organization. Pulse Survey on Continuity of Essential Health Services during the COVID-19 Pandemic. 2020. Available online: https://apps.who.int/iris/bitstream/handle/10665/334048/WHO-2019-nCoV-EHS_continuity-survey-2020.1-eng.pdf?sequence=1&isAllowed=y (accessed on 26 May 2021).
3. Barrio Cortes, J.; Suárez Fernández, C.; Bande de Oliveira, M.; Bec Martínez, M.T.; Lozano Hernández, C.; Del Cura-González, I. Health services utilization in Primary Care in patients with chronic conditions according to risk levels. Rev. Esp. Salud Publica 2019, 93, e201909082. [PubMed]
4. Vidal-Alaball, J.; Acosta-Roja, R.; Pastor Hernández, N.; Sanchez Luque, U.; Morrison, D.; Narejos Pérez, S.; Perez-Llano, J.; Salvador Verges, A.; López Seguí, F. Telemedicine in the face of the COVID-19 pandemic. Atención Primaria 2020, 52, 418–422. [CrossRef]
5. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, (9th) edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [CrossRef] [PubMed]
6. Soirguer, F.; Valdes, S.; Rojo, G. El estudio Di@bet.es, ¿y ahora qué? Av. Diabetol. 2012, 28, 35–37. [CrossRef]
7. Balanzá-Martínez, V.; Kapczinski, F.; de Azevedo Cardoso, T.; Atienza-Carbonell, B.; Rosa, A.R.; Mota, J.C.; De Boni, R.B. The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. Rev. Psiquiatr. Salud Ment. 2021, 14, 16–26. [CrossRef]
8. Torinese, G.; Conconi, V.; Monasta, L.; Carletti, C.; Faleschini, E.; Barbi, E. Glycemic Control in Type 1 Diabetes Mellitus during COVID-19 Quarantine and the Role of In-Home Physical Activity. Diabetes Technol. Ther. 2020, 22, 462–467. [CrossRef]
9. Maddalone, E.; Coraggio, L.; Pieralice, S.; Carlone, A.; Pozzilli, P.; Buzzetti, R. Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy. Diabetes Care 2020, 43, e86–e87. [CrossRef]
10. Verma, A.; Rajput, R.; Verma, S.; Balania, V.K.; Jangra, B. Impact of lockdown in COVID-19 on glycemic control in patients with type 1 Diabetes Mellitus. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1213–1216. [CrossRef]

11. Khader, M.A.; Jabeen, T.; Namouj, R. A cross sectional study reveals severe disruption in glycemic control in people with diabetes during and after lockdown in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1579–1584. [CrossRef]

12. Wang, B.; Li, R.; Lu, Z.; Huang, Y. Does comorbidiy increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging 2020, 12, 6049–6057. [CrossRef] [PubMed]

13. Li, B.; Yang, J.; Zhao, F.; Zhi, L.; Wang, X.; Liu, L.; Bi, Z.; Zhao, Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020, 109, 531–538. [CrossRef] [PubMed]

14. Tagther, G.; Mantovani, A.; Wang, X.-B.; Yan, H.-D.; Sun, Q.-F.; Pan, K.-H.; Byrne, C.D.; Zheng, K.I.; Chen, Y.-P.; Eslam, M.; et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. 2020, 46, 335–337. [CrossRef] [PubMed]

15. Comité Internacional de Clasificación de la WONCA. In Clasificación Internacional de la Atención Primaria (CIAP-2). 2ª; Masson: Barcelona, Spain, 1999.

16. Calderón-Larrañaga, A.; Vetrano, D.L.; Onder, G.; Feliu, L.A.G.; Coscoi-lar-Santaliestra, C.; Carlí, A.; Piscitoni, M.S.; Angleman, S.; Melis, R.J.; Santoni, G.; et al. Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization. J. Gerontol. Ser. A 2017, 72, 1417–1423. [CrossRef] [PubMed]

17. Lubin Pigouche, P.; Maciá Antón, M.A.; Rubio de Lemus, P. Mathemtical Psychology; Universidad Nacional de Educación a Distancia: Madrid, Spain, 2005.

18. Rissen, M.M.; Regeer, H.; Landstra, C.P.; Schröjen, M.; Jazet, I.; Nijhoff, M.F.; Pijl, H.; Ballieux, B.E.P.B.; Dekkers, O.; Huismans, S.D.; et al. Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic. BMJ Open Diabetes Res. Care 2021, 9, e002035. [CrossRef]

19. D’Onofrio, L.; Pieralice, S.; Maddaloni, E.; Migonea, C.; Sterpetti, S.; Coraggio, L.; Luordib, C.; Guarriscib, G.; Leto, G.; Leonetti, F.; et al. Effects of the COVID-19 lockdown on glycemic control in subjects with type 2 diabetes: The glyocalory study. Diabetes Obes. Metab. 2021, 23, 1624–1630. [CrossRef]

20. Eberle, C.; Stichling, S. Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: A systematic review. Diabetol. Metab. Syndr. 2021, 13, 95. [CrossRef]

21. Sociedad Española de Diabetes (SED). Un Estudio de la SED aclara la situación de la diabetes tipo 1 en España. 2019. Available online: https://www.sediabetes.org/noticias/un-estudio-de-la-sed-aclara-la-situacion-de-la-diabetes-tipo-1-en-espana/#:~:text=La%20diabetes%20tipo%201%20supone,de%20tratamiento%20espec%21ficas%20y%20complejas (accessed on 25 May 2022).

22. Yan, A.F.; Sun, X.; Zheng, J.; Mi, B.; Zuo, H.; Ruan, G.; Hussain, A.; Wang, Y.; Shi, Z. Preceived risk, behavior changes and Health-related outcomes during COVID-19 pandemic: Findings among adults with and without diabetes in China. Diabetes Res. Clin. Pract. 2020, 167, 108350. [CrossRef]

23. Joensen, L.E.; Madsen, K.P.; Holm, L.; Nielsen, K.A.; Rod, M.H.; Petersen, A.A.; Rod, N.H.; Willaing, I. Diabetes and COVID-19: A cross sectional study reveals severe disruption in glycemic control in people with diabetes during and after lockdown in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1579–1584. [CrossRef]

24. Wang, B.; Li, R.; Lu, Z.; Huang, Y. Does comorbidiy increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging 2020, 12, 6049–6057. [CrossRef] [PubMed]

25. Li, B.; Yang, J.; Zhao, F.; Zhi, L.; Wang, X.; Liu, L.; Bi, Z.; Zhao, Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020, 109, 531–538. [CrossRef] [PubMed]

26. Potier, L.; Hansel, B.; Larger, E.; Gautier, J.-F.; Carreira, D.; Assemien, R.; Lantieri, O.; Riveline, J.-P.; Roussel, R. Stay-at-Home Orders During the COVID-19 Pandemic, an Opportunity to Improve Glycemic Control Through Behavioral Changes in Type 1 Diabetes. Diabetics Care 2021, 44, 839–843. [CrossRef]

27. Yumusa, I.; Love, B.L.; Cai, C.; Hastings, T.; Reeder, C.E.; Blake, E.W.; Phillips, C. Trends in Insulin Prescribing for Patients with Diabetes During the COVID-19 Pandemic in the US. JAMA Netw. Open 2021, 4, e212607. [CrossRef] [PubMed]

28. Carr, M.J.; Wright, A.K.; Leelarathna, L.; Thabit, H.; Milne, N.; Kanumilli, N.; Ashcroft, D.M.; Rutter, M.K. Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: A UK-wide cohort study involving 618 161 people in primary care. BMJ Qual. Saf. 2021, 1–12. [CrossRef]

29. Plataforma de Organización de Pacientes. Estudio del Impacto de COVID-19 en las Personas con Enfermedad Crónica; Informe de Resultados de la 2ª Fase; POP: Madrid, Spain, 2020. Available online: https://www.plataformadepacientes.org/sites/default/files/covid19_enfermedadcronica_2021-ok2_baja_0.pdf (accessed on 11 June 2021).

30. World Health Organization. WHO NCS Department. Rapid Assessment of Service Delivery for Non Communicable Diseases (NCDs) during the COVID-19 Pandemic. 2020. Available online: https://www.who.int/docs/default-source/ncds/ncd-covid-19/for-web---rapid-assessment---30-june-2020-(cleared).pdf?sfvrsn=6296324c_20 (accessed on 26 May 2021).

31. Sal Redondo, C.; Torres Blanco, B.; Sanz Almazán, M. Satisfacción de los pacientes con la asistencia recibida por atención primaria durante los primeros meses de la pandemia de COVID-19. Med. Gen. Fam. 2020, 9, 3. [CrossRef]

32. Falcetta, P.; Aragona, M.; Ciccarone, A.; Bertolotto, A.; Campi, F.; Coppelli, A.; Dardano, A.; Giannarelli, R.; Bianchi, C.; Del Prato, S. Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy. Diabetes Res. Clin. Pract. 2021, 174, 108750. [CrossRef]

33. Sankar, P.; Ahmed, W.N.; Koshy, V.M.; Jacob, R.; Sasidharan, S. Effects of COVID-19 lockdown on type 2 diabetes, lifestyle and psychosocial health: A hospital-based cross-sectional survey from South India. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1815–1819. [CrossRef]
32. Mata-Cases, M.; Franch-Nadal, J.; Real, J.; Cedenilla, M.; Mauricio, D. Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: A population-based cross-sectional study. *BMJ Open* **2019**, *9*, e031281. [CrossRef] [PubMed]

33. Mohseni, M.; Ahmadi, S.; Azami-Aghdash, S.; Isfahani, H.M.; Moosavi, A.; Fardid, M.; Etemadi, M.; Ghazanfari, F. Challenges of routine diabetes care during COVID-19 era: A systematic search and narrative review. *Prim. Care Diabetes* **2021**, *15*, 918–922. [CrossRef] [PubMed]

34. Jaly, I.; Iyengar, K.; Bahl, S.; Hughes, T.; Vaishya, R. Redefining diabetic foot disease management service during COVID-19 pandemic. *Diabetes Metab. Syndr.* **2020**, *14*, 833–838. [CrossRef]

35. Caparrós Boixés, G.; Suñer Soler, R.; Juviny Canal, D.; Reig Garcia, G. El impacto de la pandemia de la COVID-19 en el control de las enfermedades crónicas en atención primaria. *Aten. Primaria* **2022**, *54*, 102233. [CrossRef]

36. Valabhji, J.; Barron, E.; Vamos, E.P.; Dhatariya, K.; Game, F.; Kar, P.; Weaver, A.; Verma, S.; Young, B.; Khunti, K. Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People with Diabetes in England during the COVID-19 Pandemic. *Diabetes Care* **2021**, *44*, e133–e135. [CrossRef]

37. Franch Nadal, J. Análisis Real World Data de algunas repercusiones de la pandemia de COVID-19 sobre el control metabólico de las personas con DM2. *Diabetes Pract.* **2022**, *13*. [CrossRef]